The calculator provides dose adjustment guidance based on where the current INR falls relative to the target range. An INR within the target range (commonly 2.0–3.0 for most indications) indicates therapeutic anticoagulation, and the current dose should generally be maintained. An INR below the target suggests sub-therapeutic anticoagulation, meaning the patient is not adequately protected against clot formation and may need a dose increase.

An INR above the target range indicates excessive anticoagulation and increased bleeding risk. Mildly elevated INR (just above target) may require holding one dose and a small dose reduction. Significantly elevated INR (above 4.5–5.0) requires more aggressive intervention including holding warfarin and potentially administering vitamin K. An INR above 9 is a medical emergency requiring urgent management regardless of whether active bleeding is present.

Use this tool when managing patients on warfarin anticoagulation therapy to guide dose adjustments based on INR results. Warfarin requires regular INR monitoring — typically every 1–4 weeks for stable patients, and more frequently during dose titration, initiation, or when interacting medications are started or stopped.

Common indications for warfarin therapy include atrial fibrillation (target INR 2.0–3.0), deep vein thrombosis or pulmonary embolism (target INR 2.0–3.0), mechanical heart valves (target varies by valve type and position, typically 2.5–3.5 for mitral valves), and certain hypercoagulable states. The tool helps standardize dose adjustment decisions using evidence-based protocols.

This tool provides general dose adjustment guidance and does not replace individualized clinical judgment. Warfarin dosing is affected by numerous factors including diet (vitamin K intake from green leafy vegetables), concurrent medications (antibiotics, antifungals, amiodarone, NSAIDs, and many others), alcohol consumption, liver function, thyroid status, and genetic variants in CYP2C9 and VKORC1 that affect warfarin metabolism and sensitivity.

Dose adjustments should generally be made in increments of 5–15% of the total weekly dose, and the effect of a dose change takes 3–5 days to be reflected in the INR due to warfarin's long half-life (36–42 hours) and the time needed for clotting factor turnover. Rechecking INR too soon after a dose change may lead to inappropriate further adjustments.

The tool does not account for the clinical context of INR elevation — a patient with a mildly elevated INR who is otherwise well is managed differently from one who is actively bleeding. Patients with signs of active bleeding at any INR level require emergent evaluation and may need reversal agents (vitamin K, fresh frozen plasma, or prothrombin complex concentrate) regardless of the dose adjustment guidance.